Panitumumab is under clinical development by Amgen and currently in Phase II for Triple-Negative Breast Cancer (TNBC). According to GlobalData, Phase II drugs for Triple-Negative Breast Cancer (TNBC) have a 24% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Panitumumab’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Panitumumab (Vectibix) is a recombinant, human IgG2 kappa monoclonal antibody that binds specifically to the human epidermal growth factor receptor (EGFR). It is formulated as injection concentrate and injection solution for intravenous route of administration. Vectibix is indicated for the treatment of pateients with wild-type KRAS (exon 2 in codons 12 or 13) metastatic colorectal cancer (mCRC). Vectibix is indicated as first-line treatment, in combination with the chemo regimen Folfiri for patients with wild-type (WT) RAS metastatic colorectal cancer (mCRC). Vectibix is indicated for the treatment of previously untreated patients with non-mutated (wild-type) RAS metastatic colorectal carcinoma in combination with folfox, for patients with wild-type RAS (defined as wild-type in both KRAS and NRAS as determined by an FDA-approved test for this use) metastatic colorectal cancer (mCRC) as first-line therapy in combination with FOLFOX and as monotherapy following disease progression after prior treatment with fluoropyrimidine, oxaliplatin, and irinotecan-containing chemotherapy.
Panitumumab is under development for the treatment of metastatic colorectal cancer (third line), triple-receptor negative (estrogen receptor [ER]-negative, progesterone receptor [PgR]-negative, and human epidermal growth factor receptor 2 [HER2]-negative) inflammatory breast cancer. It was also under development for metastatic esophageal squamous cell cancer, head and neck cancer squamous cell carcinoma (first line, second line), anal squamous cell carcinoma, non-small cell lung cancer (first line), adenocarcinoma of the gastroesophageal junction, gastric cancer, renal cell carcinoma, pancreatic ductal adenocarcinoma, muscle invasive bladder cancer, malignant glioma including glioblastoma multiforme and gliosarcoma.
Amgen is a biotechnology company, which discovers, develops, manufactures, and markets innovative human medicines to treat patients suffering from serious diseases. It develops novel medicines in therapeutic areas of cardiovascular, oncology/hematology, inflammation, bone health, neurological disorders and nephrology. The company develops products using advanced human genetics to analyze the difficulties of disease and understand the fundamentals of human biology. Amgen sells products primarily to pharmaceutical wholesale distributors in the US. It also markets certain products directly to consumers through direct-to-consumer channels and through partnerships with other companies. The company has presence in Asia Pacific, Europe, Middle East, North America and Australia. Amgen is headquartered in Thousand Oaks, California, the US.
For a complete picture of Panitumumab’s drug-specific PTSR and LoA scores, buy the report here.